{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:53:46Z","timestamp":1790420026371,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Swiss Sanfilippo Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ejmech.2016.09.095","type":"journal-article","created":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T14:02:53Z","timestamp":1475330573000},"page":"160-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["(5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal \u03b2-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B"],"prefix":"10.1016","volume":"126","author":[{"given":"Sophie","family":"Front","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Biela-Bana\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricie","family":"Burda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ballhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Higaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Caciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Charollais-Thoenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Gallienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Demotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier R.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2016.09.095_bib1","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ymgme.2008.04.012","article-title":"GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects","volume":"94","author":"Brunetti-Pierri","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ejmech.2016.09.095_bib2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbadis.2011.03.018","article-title":"GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings","volume":"1812","author":"Caciotti","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2016.09.095_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1590\/S1415-47572011000100009","article-title":"Population analysis of the GLB1 gene in South Brazil","volume":"34","author":"Baiotto","year":"2011","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.ejmech.2016.09.095_bib4","first-page":"33","article-title":"Therapy for lysosomal storage disorders","volume":"62","author":"Beck","year":"2010","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ejmech.2016.09.095_bib5","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2016.09.095_bib6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1750-1172-7-91","article-title":"Safety and pharmacodynamic effects of a pharmacological chaperone on \u03b1-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies","volume":"7","author":"Germain","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmech.2016.09.095_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpn.2008.03.004","article-title":"The potential action of galactose as a \u201cchemical chaperone\u201d: increase of \u03b2-galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient","volume":"13","author":"Caciotti","year":"2009","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejmech.2016.09.095_bib8","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in GM1-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2016.09.095_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2010.03.019","article-title":"DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human GM1-gangliosidosis fibroblasts","volume":"100","author":"Fantur","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ejmech.2016.09.095_bib10","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1016\/j.bmcl.2011.09.012","article-title":"A\u00a0fluorescent probe for GM1 gangliosidosis related \u03b2-galactosidase: N-(Dansylamino)hexylaminocarbonylpentyl-1,5-dideoxy-1,5-imino-d-galactitol","volume":"21","author":"Fr\u00f6hlich","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.09.095_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2012.06.007","article-title":"Evaluation of N-nonyl-deoxygalactonojirimycin as a pharmacological chaperone for human GM1 gangliosidosis leads to identification of a feline model suitable for testing enzyme enhancement therapy","volume":"107","author":"Rigat","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ejmech.2016.09.095_bib12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/mt.2012.263","article-title":"A\u00a0Bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis","volume":"21","author":"Takai","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2016.09.095_bib13","series-title":"4-Epi-isofagomine Derivatives","author":"Martin","year":"2015"},{"key":"10.1016\/j.ejmech.2016.09.095_bib14","doi-asserted-by":"crossref","first-page":"7736","DOI":"10.1016\/j.bmc.2006.08.003","article-title":"\u03b1-1-C-Octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease","volume":"14","author":"Yu","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2016.09.095_bib15","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1039\/c2cc32065g","article-title":"Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis","volume":"48","author":"Aguilar-Moncayo","year":"2012","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2016.09.095_bib16","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1021\/ja973443k","article-title":"1-N-Iminosugars: potent and selective inhibitors of \u03b2-glycosidases","volume":"120","author":"Ichikawa","year":"1998","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2016.09.095_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/cmdc.201500485","article-title":"N-Alkyl-, 1-C-alkyl-, and 5-C-alkyl-1,5-dideoxy-1,5-imino-(L)-ribitols as galactosidase inhibitors","volume":"11","author":"Front","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2016.09.095_bib18","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.1016\/j.tetlet.2004.04.121","article-title":"Synthesis of novel 1-N-iminosugars from chiral nonracemic bicyclic lactams","volume":"45","author":"Xie","year":"2004","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2016.09.095_bib19a","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.bmcl.2016.01.059","article-title":"Synthesis of C-5a-chain extended derivatives of 4-epi-isofagomine: powerful \u03b2-galactosidase inhibitors and low concentration activators of GM1-gangliosidosis-related human lysosomal \u03b2-galactosidase","volume":"26","author":"Thonhofer","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2016.09.095_bib19b","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carres.2016.03.020","article-title":"Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable \u03b2-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal \u03b2-galactosidase mutant R201C","volume":"429","author":"Thonhofer","year":"2016","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.ejmech.2016.09.095_bib20","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1002\/anie.200502662","article-title":"Rational design and synthesis of highly potent \u03b2-glucocerebrosidase inhibitors","volume":"44","author":"Zhu","year":"2005","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2016.09.095_bib21","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cbic.201100332","article-title":"Synthesis, kinetic evaluation and cell-based analysis of C-alkylated isofagomines as chaperones of \u03b2-glucocerebrosidase","volume":"12","author":"Hill","year":"2011","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2016.09.095_bib22","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1002\/1521-3765(20010903)7:17<3744::AID-CHEM3744>3.0.CO;2-3","article-title":"Efficient synthesis of isofagomine and noeuromycin","volume":"7","author":"Andersch","year":"2001","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ejmech.2016.09.095_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1042\/bj20020466","article-title":"Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins","volume":"366","author":"Mellor","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2016.09.095_bib24","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1021\/jo00222a023","article-title":"Pseudomonic acid C from l-lyxose","volume":"50","author":"Keck","year":"1985","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2016.09.095_bib25","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/chem.200701351","article-title":"The search for a potentially prebiotic synthesis of nucleotides via arabinose-3-phosphate and its cyanamide derivative","volume":"14","author":"Anastasi","year":"2008","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ejmech.2016.09.095_bib26","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1021\/ol200942g","article-title":"An isofagomine analogue with an amidine at the pseudoanomeric position","volume":"13","author":"Lindb\u00e4ck","year":"2011","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2016.09.095_bib27","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1021\/jo7027695","article-title":"Enantioselective total syntheses of omuralide, 7-epi-omuralide, and (+)-lactacystin","volume":"73","author":"Hayes","year":"2008","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2016.09.095_bib28","series-title":"Imino-sugar C-glycosides, Preparation and Use Thereof","author":"Sollogoub","year":"2014"},{"key":"10.1016\/j.ejmech.2016.09.095_bib29","doi-asserted-by":"crossref","first-page":"10983","DOI":"10.1039\/c3cc46646a","article-title":"Selective trihydroxyazepane NagZ inhibitors increase sensitivity of Pseudomonas aeruginosa to \u03b2-lactams","volume":"49","author":"Mondon","year":"2013","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2016.09.095_bib30","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1021\/bi301223f","article-title":"Functional screening of pharmacological chaperones via restoration of enzyme activity upon denaturation","volume":"51","author":"Meera Shanmuganathan","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2016.09.095_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/humu.21516","article-title":"Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in \u03b2-galactosidase deficiency","volume":"32","author":"Higaki","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2016.09.095_bib32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1399-0004.2007.00843.x","article-title":"Identification of a novel pseudodeficiency allele in the GLB1 gene in a carrier of GM1 gangliosidosis","volume":"72","author":"Gort","year":"2007","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ejmech.2016.09.095_bib33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev-genom-090711-163739","article-title":"Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges","volume":"13","author":"Desnick","year":"2012","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.ejmech.2016.09.095_bib34","doi-asserted-by":"crossref","first-page":"14560","DOI":"10.1074\/jbc.M113.529529","article-title":"Structural basis of pharmacological chaperoning for human \u03b2-galactosidase","volume":"289","author":"Suzuki","year":"2014","journal-title":"J.\u00a0Biol. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416308583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523416308583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T05:37:41Z","timestamp":1556343461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523416308583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":35,"alternative-id":["S0223523416308583"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.095","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"(5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal \u03b2-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}